Financial Projections for 2024 - The company expects a net profit attributable to shareholders for 2024 to be approximately between -650 million and -580 million CNY[3]. - The estimated operating revenue for 2024 is projected to be between 320 million and 360 million CNY[4]. - The net profit after deducting non-recurring gains and losses is expected to be between -450 million and -370 million CNY for 2024[3]. - The estimated total profit for 2024 is projected to be between -650 million and -600 million CNY[4]. - The company's net assets at the end of 2024 are expected to be approximately between 40 million and 60 million CNY[3]. Previous Year Performance - The previous year's net profit attributable to shareholders was -464.71 million CNY, with an operating revenue of 285.69 million CNY[6]. Reasons for Expected Loss - The main reasons for the expected loss include an investment loss of approximately -247 million CNY from the equity held in a bank and impairment losses of about 200 million CNY on inventory and fixed assets[7]. Delisting Risk - The company’s stock has been under delisting risk warning since April 30, 2024, due to an audit report with no opinion expressed[8]. - If the audited net assets for 2024 are negative, the company’s stock may face delisting risk[9]. Financial Data Status - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the official annual report[10].
宁科生物(600165) - 2024 Q4 - 年度业绩预告